VEEV · Veeva Systems Inc
Price
Snapshot
50 fields · last close| Market Cap | $50.25B |
| P/E | 49.52 |
| Float | 148.3M |
| Beta | 0.88 |
| Volatility | 22.1% |
| Exchange | NYSE |
| Sector | Health Care |
| Cap tier | Large cap |
| Macro sensitivity | Moderate |
| Clavix score | 67.4 |
| Price | 316.79 |
| Change | +2.07% |
| Prev Close | 310.36 |
| Open | 319.95 |
| Day Low | 306.57 |
| Day High | 319.95 |
| Avg Vol | 2 |
| Avg $ Vol | $484.7M |
| 52W High | 319.95 |
| 52W Low | 148.05 |
| 52W Pos | 98.2% |
| From High | −0.99% |
| From Low | +113.98% |
| Max DD 1Y | −49.37% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | +11.23% |
| SMA 50 | +17.85% |
| SMA 200 | +54.63% |
| RSI (14) | 71.2 |
| Vol 30D | 33.6% |
| Vol 90D | 45.0% |
| 1Y Range | 148–320 |
| Daily bars | 536 |
| Perf Week | +4.81% |
| Perf Month | +17.67% |
| Perf Quarter | +57.22% |
| Perf Half Y | +84.79% |
| Perf Year | +8.00% |
| Perf YTD | +44.33% |
| Prev Day | +2.07% |
| Clavix | B- |
| Debt / Eq | 0.00 |
| Curr Ratio | 4.89 |
| Int Cover | 189.7× |
| FCF Margin | 44.3% |
| Rev Growth | +16.3% |
| Profit | Profitable |
| Leverage | Low |
| Sector rank | 45 / 49 |
Clavix risk grade
regraded every trading dayVEEV grades B-, 67.4 of 100. Steadiest on Sector Resilience (71), most exposed on Price Stability (52, mixed). 1 of the 4 weighted dimensions sit above the Health Care median. Ranks 45 of 49 in Health Care by Clavix score.
How rough the ride is
| VEEV | Health Care median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.88 | 0.84 |
| Volatilityannualized | 22.1% | 20.9% |
| Max drawdown, past yearworst peak-to-trough fall | −49.4% | — |
| Typical daily movemedian absolute daily change | 1.27% | — |
| Days beyond ±3%of the last 252 sessions | 60 (24%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| VEEV | Health Care median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.88 | 0.84 |
| Macro sensitivityrate, dollar and credit exposure bucket | Moderate | Moderate 53% of 49 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Health Care names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| VEEV | |
|---|---|
| 1 week | +4.8% |
| 1 month | +17.7% |
| Year to date | +44.3% |
| 1 year | +8.0% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| VEEV | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 27 Aug |
| Average score0 most bearish, 100 most bullish | 73 |
| Bullish · bearisharticles above 60 · below 40 | 28 · 2 |
| Directionarticles whose tone is improving vs worsening | 28 ↑ 2 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 49 Health Care names Clavix covers; the tick is the sector median.
Growth
| VEEV | |
|---|---|
| Revenue growthyear over year | +16.3% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Health Care median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openIQVIA picked Veeva's clinical software suite, including systems for managing trials, organizing trial documents, starting up studies and connecting with trial sites, as its standard across clinical studies, building on an earlier data-capture partnership. Separately, Veeva said more than 175 small biotechs are now using its Basics software bundle.
IQVIA, one of the world's largest contract research organizations, will standardize on Veeva's clinical software suite across all of its global research studies. The expanded deal covers four Veeva products used to run and document clinical trials.
Veeva is expanding its existing partnership with IQVIA to include a clinical operations software suite, a set of tools used to manage and run clinical trials for new drugs. The article says the move is meant to broaden Veeva's market reach through wider customer adoption and more integrated workflows.
Veeva is expanding its existing partnership with IQRIA to include a clinical operations software suite, which the company says will widen adoption and integrate workflows between the two firms.
Veeva Systems shares rose 2.8% after IQVIA chose Veeva's clinical operations software as its company-wide standard for running clinical trials. The stock closed at $301.71, up about 2% for the day.
Nearest peers by size
Health Care| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| EW | Edwards Lifesciences Corp | A- | $49.92B | 49.67 | 0.84 | Compare |
| HUM | Humana Inc | B | $49.61B | 38.79 | 0.67 | Compare |
| BDX | Becton Dickinson and Co | A- | $52.23B | 55.45 | 0.24 | Compare |
| MDLN | Medline Inc | B | $47.28B | 68.22 | 0.95 | Compare |
| IDXX | IDEXX Laboratories Inc | B+ | $44.15B | 38.74 | 1.55 | Compare |
| CAH | Cardinal Health Inc | A- | $58.83B | 34.32 | 0.54 | Compare |
| BSX | Boston Scientific Corp | B | $64.33B | 17.51 | 0.59 | Compare |
| COR | Cencora Inc | B+ | $65.06B | 24.79 | 0.58 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.